Recorded Webcast - Optimizing Immuno-Oncology: Innovations in Immune Checkpoint Inhibitor Delivery

This accredited continuing education activity “Recorded Webcast - Optimizing Immuno-Oncology: Innovations in Immune Checkpoint Inhibitor Delivery”, is recorded from the live webinar held on 03/01/2025. The recorded lectures and subsequent discussions are designed to address evolving approaches in immune checkpoint inhibitor (ICI) administration, the program focuses on both intravenous (IV) and subcutaneous (SC) delivery methods across multiple tumor types. This program provides healthcare providers with insights into integrating SC ICI administration into practice, selecting appropriate treatment plans, and managing adverse events effectively. Emphasizing a multidisciplinary approach, participants will gain practical tools to improve clinic efficiency, patient adherence, and safety, enhancing patient outcomes in immuno-oncology.

Important information about claiming continuing education credits (CME/MOC, ACPE, Nursing contact hours) for this activity:

If you participated in the live webinar titled - Optimizing Immuno-Oncology: Innovations in Immune Checkpoint Inhibitor Delivery on 03/01/2025 and claimed CME credits/MOC points for that activity, you do not qualify for CME credits/MOC points for your participation in this enduring activity. This is a recorded content from that webinar on 03/01/2025.  However, you may enroll in this activity to review the contents. 

Target Audience

  • Medical Oncologists
  • Fellows
  • Advanced Practice Providers
  • Pharmacists
  • Nurses

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  • Evaluate the benefits and limitations of IV versus SC administration of immune checkpoint inhibitors across diverse tumor types. 
  • Analyze current evidence on the efficacy, safety, and pharmacokinetics of SC versus IV ICIs in managing patients with cancer.
  • Integrate SC ICI administration into practice through multidisciplinary team approaches that enhance efficiency and patient experience.
  • Implement strategies to monitor and manage adverse events associated with SC ICIs to ensure patient safety and improve adherence.

You may also be interested in

Central Illinois Hematology Oncology Conference

The Central Illinois Hematology Oncology Conference is an accredited continuous education to improve the care of cancer patients by educating cancer care providers about precision-guided management in hematology and oncology.
Hematology Oncology Practice Symposium, Detroit

This accredited continuing education activity, the Hematology Oncology Practice Symposium in Detroit, is designed to enhance cancer care by integrating the latest advances into clinical practice.
Summit on Cancer Health Disparities (SCHD25)

The Summit on Cancer Health Disparities 2025 (SCHD25) is a premier annual event focused on addressing cancer health disparities. The conference serves to bridge research and practice, offering practical strategies to improve cancer care delivery and outcomes.
Course summary
Available credit: 
  • 1.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 1.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 1.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 1.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 1.00 Contact Hours.
Course opens: 
03/12/2025
Course expires: 
03/12/2026
Cost:
$0.00

This educational activity features recorded videos from the live webinar titled, Optimizing Immuno-Oncology: Innovations in Immune Checkpoint Inhibitor Delivery held on 03/01/2025.

The videos are placed in the following order. Feel free to view the content that is relevant to you.

Participants should claim continuing education credits to the extent of their participation.

20 minutes - Innovations in ICI Administration – Latest Advances and Implications for Practice - Shailender Bhatia, MD

20 minutes - Comparing IV and SC Administration of ICIs – Clinical Evidence and Practical Considerations - Petros Grivas, MD, PhD

20 minutes - Q&A

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Speaker/Topic Presenter(s)

Shailender Bhatia, MD

has a financial relationship (Grant Or Contract) with Bristol Meyers Squibb;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Professional Services) with Replimune;.
has a financial relationship (Grant Or Contract) with Agenus;.
has a financial relationship (Grant Or Contract) with Incyte;.
has a financial relationship (Professional Services) with Incyte;.
has a financial relationship (Grant Or Contract) with EMD Serono;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Grant Or Contract) with Regeneron (fka Checkmate Pharmaceuticals);.
has a financial relationship (Grant Or Contract) with Trisalus Life Sciences;.
has a financial relationship (Professional Services) with Regeneron;.

Petros Grivas, MD, PhD

has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Grant Or Contract) with QED Therapeutics;.
has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with Fresenius Kabi;.
has a financial relationship (Professional Services) with Asieris Pharmaceuticals;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with ALX Oncology;.
has a financial relationship (Professional Services) with Bicycle Therapeutics;.
has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with Gilead Sciences;.
has a financial relationship (Professional Services) with Immunity Bio;.
has a financial relationship (Grant Or Contract) with BMS;.
has a financial relationship (Grant Or Contract) with Acrivon Therapeutics;.
has a financial relationship (Grant Or Contract) with MSD;.
has a financial relationship (Professional Services) with Foundation Medicine;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Astellas Pharma;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Grant Or Contract) with Gilead Sciences;.
has a financial relationship (Professional Services) with MSD;.
has a financial relationship (Professional Services) with Replimune;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Roche;.
has a financial relationship (Professional Services) with Strata Oncology;.

Commercial Support Acknowledgment

This activity is supported with an independent medical education grant from Merck.

Important Information about Claiming continuing education credits or MOC points for this activity

This accredited continuing education activity “Recorded Webcast - Optimizing Immuno-Oncology: Innovations in Immune Checkpoint Inhibitor Delivery”, is recorded from the live webinar held on 03/01/2025. 

If you participated in the live webinar titled - Optimizing Immuno-Oncology: Innovations in Immune Checkpoint Inhibitor Delivery on 03/01/2025 and claimed CME credits/MOC points for that activity, you do not qualify for CME credits/MOC points for your participation in this enduring activity. This is a recorded content from that webinar on 03/01/2025.  However, you may enroll in this activity to review the contents. 

ACPE Pharmacy CEU

The Binaytara Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The ACPE Universal Activity Number assigned to the activity is 0686-0000-25-001-H01-P.  The Binaytara Foundation designates this activity for a maximum of 1.00 pharmacy CEUs. 

Participants must pass the post-test, complete course evaluation, and provide their NABP e-Profile ID number (ePID) and Date of Birth (MMDD) to Binaytara foundation within 30-days of participating in the activity. Participants who do not complete these requirements within 30-days of participating in the live activity will not be awarded the CEUs.

The Binaytara foundation may distribute a participation certificate containing information provided to NABP from the Accreditation Council for Pharmacy Education (ACPE) via CPE Monitor®. ACPE policy states paper and/or electronic statements of credit may no longer be distributed directly to learners as proof of ACPE credit. The official record of credit may be located in the learner’s e-profile in CPE Monitor®.

Available Credit

  • 1.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 1.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 1.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 1.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 1.00 Contact Hours.

Price

Cost:
$0.00
Please login or register to take this course.

REGISTRATION FEES

This activity is free for all healthcare providers. 

Cancellation Policy

You may cancel your enrollment at any time. No credits will be offered if you do not complete all required steps of this activity which include registration, watching the recorded content, and completion of pre & post tests as well as course evaluations.